Article
CCR2-64I and CXCL12 3'A alleles confer a favorable prognosis to AIDS patients undergoing HAART therapy.
Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology - 1 Dec 2005
Passam Andrew M, Zafiropoulos Alexandros, Miyakis Spiros, Zagoreos Ioannis, Stavrianeas Nikolaos G, Krambovitis Elias, Spandidos Demetrios A
Abstract excerpt
BACKGROUND: The chemokine receptor polymorphisms CCR5Delta32, CXCL12 3'A, CCR2-64I and CCR5-59029 G/A have been demonstrated to affect HIV-1 infection and progression. OBJECTIVE: We studied the impact of the above polymorphisms on the effectiveness of a 30-month treatment with highly active antiretroviral therapy (HAART) in 149 HIV-1 patients. STUDY DESIGN: We stratified the patients according to CD4 CDC criteria...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
